Compare Davita Inc (DVA) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Prologis Inc — how do they compare? Davita Inc trades at $179.02 (market cap $11.72B), while Prologis Inc trades at $139.07 (market cap $133.20B). The key difference: Prologis Inc is far larger — about 11.4× Davita Inc's market cap, and Prologis Inc pays a 3.05% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | PLD | |
|---|---|---|
Market Cap | $11.72B | $133.20B |
Sector | Health | Real Estate |
52-Week High | $240.96 | $149.96 |
52-Week Low | $103.87 | $104.81 |
Enterprise Value | $24.44B | $167.94B |
Dividend Yield | — | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Prologis (PLD) trades at $140.16, up 0.73% on the day, with a bearish technical signal but strong fundamentals including a 45.79% net income margin and consistent earnings beats. Recent news highlights the acquisition of SEGRO for up to $19.2 billion, expanding its European footprint, alongside a common stock offering to fund growth. Cash flow trends show variability, with 2025 net cash flow negative at -$172.94 million but projected to rebound in 2026.
The outlook is positive due to robust earnings growth, strategic acquisitions, and a 57% analyst buy rating with a $159.22 price target. Risks include high debt levels, with debt-to-asset ratio rising to 37.2 in 2025, and integration challenges from the SEGRO deal. Investors should weigh strong profitability against leverage and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
